Longeveron Q1 revenue rises, beats analyst estimates

Longeveron

13/05/2026 21:24

Overview

US biotech firm's Q1 revenue rose and beat analyst expectations

Net loss for Q1 narrowed from prior year

Company closed $30 mln private placement, with $15 mln funded initially

Outlook

Company expects August 2026 top-line results from Phase 2b HLHS clinical trial

Company anticipates initiating Phase 2 PDCM clinical trial in 2027

Longeveron expects cash and equivalents to fund operations into Q4 2026

Result Drivers

CLINICAL TRIAL DEMAND - Higher clinical trial revenues driven by increased participant demand for Bahamas Registry Trial

CONTRACT MANUFACTURING DECLINE - Lower contract manufacturing revenues due to reduced demand from third-party client

COST MANAGEMENT - Decrease in general and administrative and R&D expenses primarily from lower personnel and incentive costs

Company press release: ID:nGNX75jY4m

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$398,000
$314,670 (3 Analysts)
Q1 EPS
-$0.19
Q1 Net Income
-$4.73 mln
Q1 Gross Profit
$264,000
Q1 Income from Operations
-$4.78 mln
Q1 Operating Expenses
$5.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Longeveron Inc is $6.00, about 699.9% above its May 12 closing price of $0.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)